4.7 Article

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

R. K. Murthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Review Genetics & Heredity

Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

J. M. Campbell et al.

PHARMACOGENOMICS JOURNAL (2017)

Review Medicine, General & Internal

Triple-Negative Breast Cancer

William D. Foulkes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Oncology

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA

Mary Jo Lund et al.

BREAST CANCER RESEARCH AND TREATMENT (2009)

Article Oncology

Triple-negative breast cancer: Clinical features and patterns of recurrence

Rebecca Dent et al.

CLINICAL CANCER RESEARCH (2007)

Article Medicine, General & Internal

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

Lisa A. Carey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)